Liver Inflammation Panel

Description

The Liver Inflammation Panel from BiomarkersLabs.com is a focused hepatic inflammatory activity assessment providing markers specifically relevant to ongoing hepatocellular inflammatory processes in patients with established or suspected chronic liver disease — going beyond the standard LFT panel to include markers of hepatic inflammation, fibrosis, and oxidative stress that more precisely characterise the inflammatory activity driving liver disease progression. Where standard LFTs provide a snapshot of enzyme levels, the Liver Inflammation Panel is designed for serial monitoring of hepatic inflammatory activity in patients with confirmed chronic liver conditions — including NAFLD/NASH, autoimmune hepatitis, chronic viral hepatitis, and medication-induced chronic hepatic injury — where tracking the degree of active inflammation guides treatment decisions and identifies patients at risk of progressive fibrosis. Specimens processed through CLIA-certified partner laboratories. Results delivered within 2–4 business days. Available in USA · EU · UK · Canada. Licensed practitioners only.

What does this panel measure?

ALT and AST — Hepatocellular inflammatory markers as part of the inflammation panel context.

GGT — Biliary and oxidative stress marker elevated in chronic hepatic inflammation and alcohol-related hepatic injury.

Ferritin — Acute phase reactant elevated in hepatic inflammation and iron overload states including haemochromatosis and NASH.

Additional hepatic inflammation markers as included in the specific panel configuration — which may include high-sensitivity CRP (systemic inflammatory contribution to hepatic disease), alkaline phosphatase, and bilirubin.

Clinical indications

Hepatic inflammation monitoring in chronic liver disease — serial inflammatory marker tracking in patients with NAFLD, NASH, autoimmune hepatitis, chronic hepatitis B or C, and alcohol-related liver disease.

Monitoring response to liver-protective therapy — tracking hepatic inflammatory marker changes during treatment with ursodeoxycholic acid, silymarin (milk thistle), N-acetylcysteine, antiviral therapy, or immunosuppressive agents.

NAFLD/NASH activity assessment — elevated ALT, AST, and ferritin in the context of metabolic risk factors characterises NASH severity and guides decisions about liver biopsy.

Autoimmune hepatitis monitoring — serial ALT, AST, and GGT track disease activity and immunosuppressive treatment adequacy in autoimmune hepatitis.

Medication-induced hepatotoxicity surveillance — serial hepatic inflammation markers during hepatotoxic drug therapy identify early DILI before progression to significant hepatocellular injury.

Sample type and collection

Blood (serum). No fasting required. 2–4 business days. USA · EU · UK · Canada. No New York restriction. CLIA · IVDR · CE · HIPAA · GDPR · PIPEDA. Register free at BiomarkersLabs.com. Licensed practitioners only. Pay per test.